Hemerion ships its devices to Erasmus Hospital

Hemerion technology to be further evaluated in the DOSINDYGO multi-center clinical trial

The Hemerion technology, which associates drugs and photonic treatments against glioblastoma, is to be evaluated in the DOSINDYGO clinical trial.This new clinical trial is sponsored by CHU de Lille (PI Nicolas REYNS) and the Brussels Erasmus Hospital (PI Florence Lefranc) with the financial support of Fonds Erasme. Following the INDYGO trial which assessed the Hemerion …

Hemerion at the Brain Tumor Symposium in Miami

The Hemerion technology presented at the Miami Global Brain Tumor Symposium

Pr. Nicolas Reyns, Head of the neurosurgery oncology dept. of the University Hospital of Lille, has been developing photodynamic therapy since 2010 in partnership with the Inserm laboratory U1189 OncoThAI. He notably spearheaded ground-breaking glioblastoma treatments and co-invented the technology now developed by Hemerion. Pr. Reyns has presented his experience developing photodynamic therapy for glioblastoma …